Comparison · NCT02836496-sae
Mepolizumab 300 mg SC vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Mepolizumab 300 mg SC vs Placebo: serious adverse events. Trial comparisons, record NCT02836496-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02836496-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.185 | 0.104 | 0.308 | wilson | |
| Risk in group 2 | 0.167 | 0.0902 | 0.287 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0185 | -0.127 | 0.163 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.11 | 0.49 | 2.52 | log | |
| Odds ratio, group 1 over group 2 | 1.14 | 0.421 | 3.06 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Mepolizumab 300 mg SC than on Placebo | 54 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Mepolizumab 300 mg SC | Participants were randomized to receive 300 mg mepolizumab SC every 4 weeks during the 32-Week treatment period while continuing their HES therapy. The final dose was administered at Week 28 with the completion of study treatment period achieved in the next 4-weekly visit. | 10 | 54 | EG001 |
| Group 2 | Placebo | Participants were randomized to receive matching placebo SC every 4 weeks during the 32-Week treatment period while continuing their HES therapy. The final dose was administered at Week 28 with the completion of study treatment period achieved in the next 4-weekly visit. | 9 | 54 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Non-serious adverse events (non-SAEs) from start of study treatment until 28 days after last dose (Up to 32 weeks) are reported. Serious adverse events (SAEs) were collected from the day of randomization (Week 0) up to end of study (Up to Week 40).
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
- NCT number
- NCT02836496
- Phases
- PHASE3
- Conditions
- Hypereosinophilic Syndrome
- Interventions
- Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2020-02-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02836496?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02836496-sae